Citations

Showing 10 of 108162 citations.

In Vivo Comparison of Radiation Exposure in Third-Generation vs Second-Generation Dual-Source Dual-Energy CT for Imaging Urinary Calculi
Lam, Jonathan P. , Alexander, Lauren F. , William, Haley E., Hodge, David O. , Kofler, James M., Morin, Richard L. , Thiel, David D. , Cernigliaro, Joseph G. , Alexander, Lauren F

Mayo Clinic

Journal of Endourology | April 16, 2021 | Volume: 35 | Issue: 11 | Pages: 1581-1585

10.1089/end.2021.0103 | PMID 33858196 Get It

Purpose: To investigate the potential for decreasing radiation dose when utilizing a third-generation vs second-generation dual-source dual-energy CT (dsDECT) scanner, while maintaining diagnostic image quality and acceptable image noise. Materials and Methods : Retrospective analysis of patients who underwent dsDECT for clinical suspicion of urolithiasis from October 2, 2017, to September 5, 2018. Patient demographics, body mass index, abdominal diameter, scanning parameters, and CT dose index volume (CTDIvol) were recorded. Image quality was assessed by measuring the attenuation and standard deviation (SD) regions of interest in the aorta and in the bladder. Image noise was determined by averaging the SD at both levels. Patients were excluded if they had not undergone both third- and second-generation dual-energy CT (DECT), time between DECT was more than 2 years, or scan parameters were outside the standard protocol. Results: A total of 117 patients met the inclusion criteria. Examinations performed on a third-generation DECT had an average CTDIvol 12.3 mGy, while examinations performed on a second-generation DECT had an average CTDIvol 13.3 mGy ( p < 0.001). Average image noise was significantly lower for the third-generation DECT (SD = 10.3) compared with the second-generation DECT (SD = 13.9) ( p < 0.001). Conclusions: The third-generation dsDECT scanners can simultaneously decrease patient radiation dose and decrease image noise compared with second-generation DECT. These reductions in radiation exposure can be particularly important in patients with urinary stone disease who often require repeated imaging to evaluate for stone development and recurrence as well as treatment assessment.
Informing Information Professionals: A Case Report on Creating a Shared Site of Pandemic Resources
Aaronson, Ellen , Spencer, Angela

Mayo Clinic

Journal of Hospital Librarianship | April 15, 2021 | Volume: 21 | Issue: 2 | Pages: 198-201

10.1080/15323269.2021.1899789 Get It

177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Şanlı, Yasemin , Subramaniam, Rathan M. , Kendi, A. Tuba , Kendi, A Tuba , Şimşek, Duygu Has , Şanlı, Öner

Mayo Clinic

Biomedicines | April 15, 2021 | Volume: 9 | Issue: 4 | Pages: 430

10.3390/biomedicines9040430 | PMID 33921146 Get It

The aim of this narrative review is to evaluate the current status of 177Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration and side effect profiles. 177Lu-PSMA therapy efficacy was assessed by using prospective trials, meta-analyses and major retrospective trials. Predictors of efficacy were also mentioned. Although there are some different approaches regarding the use of 177Lu-PSMA therapy in different countries, this type of therapy is generally safe, with a low toxicity profile. From the oncological point of view, a PSA (prostate specific antigen) decline of ≥50% was seen in 10.6–69% of patients with mCRPC; whereas progression-free survival (PFS) was reported to be 3–13.7 months in different studies. Consequently, 177Lu-PSMA therapy is a promising treatment in patients with mCRPC, with good clinical efficacy, even in heavily pretreated patients with multiple lines of systemic therapy. Currently, there are ongoing clinical trials in the United States, including a phase III multicenter FDA registration trial.
Hydrogen peroxide‐producing electrochemical bandage controlled by a wearable potentiostat for treatment of wound infections
Anoy, Md Monzurul Islam , Tibbits, Gretchen , Raval, Yash S. , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Flurin, Laure , Patel, Robin , Mohamed, Abdelrhman , Beyenal, Haluk , Raval, Yash S.

Mayo Clinic

Biotechnology and Bioengineering | April 15, 2021 | Volume: 118 | Issue: 7 | Pages: 2815-2821

10.1002/bit.27794 | PMID 33856049 Get It

AbstractChronic wound infections caused by biofilm‐forming microorganisms represent a major burden to healthcare systems. Treatment of chronic wound infections using conventional antibiotics is often ineffective due to the presence of bacteria with acquired antibiotic resistance and biofilm‐associated antibiotic tolerance. We previously developed an electrochemical scaffold that generates hydrogen peroxide (H2O2) at low concentrations in the vicinity of biofilms. The goal of this study was to transition our electrochemical scaffold into an H2O2‐generating electrochemical bandage (e‐bandage) that can be used in vivo. The developed e‐bandage uses a xanthan gum‐based hydrogel to maintain electrolytic conductivity between e‐bandage electrodes and biofilms. The e‐bandage is controlled using a lightweight, battery‐powered wearable potentiostat suitable for use in animal experiments. We show that e‐bandage treatment reduced colony‐forming units of Acinetobacter buamannii biofilms (treatment vs. control) in 12 h (7.32 ± 1.70 vs. 9.73 ± 0.09 log10[CFU/cm2]) and 24 h (4.10 ± 12.64 vs. 9.78 ± 0.08 log10[CFU/cm2]) treatments, with 48 h treatment reducing viable cells below the limit of detection of quantitative and broth cultures. The developed H2O2‐generating e‐bandage was effective against in vitro A. baumannii biofilms and should be further evaluated and developed as a potential alternative to topical antibiotic treatment of wound infections.
Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
Pereira, Felipe Moraes Toledo , Silva, Adriano Gonçalves e , Dettino, Aldo Lourenço Abbade , Cardoso, Ana Paula Garcia , Kann, Ariel Galapo , Dzik, Carlos, Herchenhorn, Daniel , Jardim, Denis L. , Lopera, Diego , Ayadi, Mouna , Salman, Pamela, Carvalho, Ricardo Saraiva de , Cavalléro, Sandro Roberto de Araújo , Aguiar, Sergio, Souza, Vinícius Carrera , Usón, Pedro Luiz Serrano , Soares, Andrey , Kann, Ariel Galapo , Herchenhorn, Daniel , Jardim, Denis Leonardo Fontes , Lopera, Diego , Kopp, Ray Antonio Manneh , Cavallero, Sandro Roberto De Araujo , Uson Junior, Pedro Luiz Serrano, Soares, Andrey , Uson, Pedro L S , Sasse, Andre Deeke , Salman, Pamela

Mayo Clinic

JCO Global Oncology | April 15, 2021 | Volume: No volume available | Issue: 7 | Pages: 545-549

10.1200/go.20.00507 | PMID 33856892 Get It

PURPOSE To present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the Prostate Cancer Consensus Conference for Developing Countries. METHODS A total of 27 questions were identified as relating to this topic. Responses from the clinician were tallied and are presented in percentage format. Topics included the use of imaging in staging, treatment recommendations across different patient scenarios of life expectancy and prostate-specific antigen (PSA) doubling time, and follow-up for nonmetastatic castration-resistant PCa. RESULTS A consensus agreed that in optimal conditions, positron emission tomography-computed tomography with prostate-specific membrane antigen would be used although in limited resource situations the combined use of CT of the abdomen and pelvic (or pelvic MRI), a bone scan, and a CT of the thorax or chest x-ray was recommended. In cases when PSA levels double in < 10 months, more than 90% of clinicians agreed on the use of apalutamide or enzalutamide, regardless of life expectancy. With a doubling time of more than 10 months, > 54% of experts recommended no treatment independent of life expectancy. More than half of the experts, regardless of resources, recommended follow-up with a physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms. CONCLUSION The voting results and recommendations presented in this document can be used by physicians to support management for biochemical recurrence of castration-resistant PCa in areas of limited resources. Individual clinical decision making should be supported by available data.
A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
Nanda, S. , Toussaint, Loren , Vincent, Ann, Schroeder, Darrell R. , Chacin‐Suarez, Audry , Medina‐Inojosa, José R. , O’Horo, John C. , DeJesus, Ramona S. , Lebdeh, Haitham S. Abu, Iftikhar, Salma , Croghan, Ivana T. , Hurt, Ryan, Chacin Suarez, Audry S, Medina Inojosa, Jose R, O'Horo, John C, Abu Lebdeh, Haitham S, Croghan, Ivana T , Toussaint, Loren L , Medina-Inojosa, José R , O'Horo, John C , Schroeder, Darrell , Fischer, Karen M. , Hurt, Ryan T. , Mundi, Manpreet S. , Chacin Suarez, Audry S

Mayo Clinic

Journal of Primary Care & Community Health | April 15, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211010991 | PMID 33855875 Get It

Objective To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. Patients and Methods A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. Results Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. Conclusion In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes.
Diabetic ketoacidosis drives COVID‐19 related hospitalizations in children with type 1 diabetes
Alonso, G. Todd , Ebekozien, Osagie , Gallagher, Mary , Rompicherla, Saketh, Lyons, Sarah K. , Choudhary, Abha , Majidi, Shideh , Pinnaro, Catherina T. , Balachandar, Sadana, Gangat, Mariam , Marks, Brynn E. , Creo, Ana L. , Sanchez, Janine , Seeherunvong, Tossaporn, Jimenez‐Vega, Jose , Patel, Neha S. , Gabriel, Liana , Sumpter, Kathryn , Wilkes, Meredith , Rapaport, Robert , Cymbaluk, Anna, Wong, Jenise C. , Sanda, Srinath , Albanese-O’Neill, Anastasia , Alonso, Guy Todd , Creo, Ana , Wilkes, Meredith , Wong, Jenise C , Roberts, Alissa Jeanne Curda , Wood, Jamie

Mayo Clinic

Journal of Diabetes | April 15, 2021 | Volume: 13 | Issue: 8 | Pages: 681-687

10.1111/1753-0407.13184 | PMID 33855813 Get It

AbstractBackgroundDiabetes is a risk factor for poor COVID‐19 outcomes, but pediatric patients with type 1 diabetes are poorly represented in current studies.MethodsT1D Exchange coordinated a US type 1 diabetes COVID‐19 registry. Forty‐six diabetes centers submitted pediatric cases for patients with laboratory confirmed COVID‐19. Associations between clinical factors and hospitalization were tested with Fisher's Exact Test. Logistic regression was used to calculate odds ratios for hospitalization.ResultsData from 266 patients with previously established type 1 diabetes aged <19 years with COVID‐19 were reported. Diabetic ketoacidosis (DKA) was the most common adverse outcome (n = 44, 72% of hospitalized patients). There were four hospitalizations for severe hypoglycemia, three hospitalizations requiring respiratory support (one of whom was intubated and mechanically ventilated), one case of multisystem inflammatory syndrome in children, and 10 patients who were hospitalized for reasons unrelated to COVID‐19 or diabetes. Hospitalized patients (n = 61) were more likely than nonhospitalized patients (n = 205) to have minority race/ethnicity (67% vs 39%, P < 0.001), public insurance (64% vs 41%, P < 0.001), higher A1c (11% [97 mmol/mol] vs 8.2% [66 mmol/mol], P < 0.001), and lower insulin pump and lower continuous glucose monitoring use (26% vs 54%, P < 0.001; 39% vs 75%, P < 0.001). Age and gender were not associated with risk of hospitalization. Higher A1c was significantly associated with hospitalization, with an odds ratio of 1.56 (1.34‐1.84) after adjusting for age, gender, insurance, and race/ethnicity.ConclusionsHigher A1c remained the only predictor for hospitalization with COVID‐19. Diabetic ketoacidosis is the primary concern among this group.
Development of a Theory-Informed Behavior Change Intervention to Reduce Inappropriate Prescribing of Nephrotoxins and Renally Eliminated Drugs
Kane‐Gill, Sandra L. , Frazee, Erin N. , Bihorac, Azra , Kellum, John A. , Frazee, Erin N , Kane-Gill, Sandra L , Kellum, John A , Bihorac, Azra

Mayo Clinic

Annals of Pharmacotherapy | April 15, 2021 | Volume: 55 | Issue: 12 | Pages: 1474-1485

10.1177/10600280211009567 | PMID 33855858 Get It

Background: Goals of managing patients with acute kidney injury (AKI) are mitigating disease progression and ensuring safety while providing supportive care because no effective treatment exists. One strategy recommended in guidelines to meet these goals is optimizing medication management. Unfortunately, guideline implementation appears to be lacking as observed by the frequent occurrence of medication errors and adverse drug events. Objective: To address this performance gap in the care of hospitalized patients receiving nephrotoxins and renally eliminated drugs, we sought to provide a potential intervention based on theory-informed behavior change. Methods: Formative research with a qualitative analysis identifying what needs to change in patient care was completed by obtaining clinician opinion and expert opinion and reviewing the published literature. Frontline providers, including 8 physicians, 4 pharmacists, and a multiprofessional group of authors, provided insight into possible barriers to appropriate prescribing. Capability, Opportunity, Motivation and Behavior model and Theoretical Domain Framework were applied to characterize behavior change interventions and inform a potential implementation intervention for changing inappropriate prescribing behaviors. Results: Lack of knowledge about appropriate drug management in patients at risk for adverse outcomes was provided as a major barrier. Other reported barriers included a lack of: (1) tools to assist with drug management, (2) motivation to make changes, (3) routinization, and (4) an accountable clinician. Conclusions and Relevance: Assigning a designated clinician to execute a stepwise, routine care process following the checklist provided is a recommended intervention to overcome barriers. The intended impact is behavior change that reduces inappropriate prescribing.
Study of EHR-mediated workflows using ethnography and process mining methods
Vellore, Vaishak, Duncan, Benjamin J. , Furniss, Stephanie K, Doebbeling, Bradley N. , Poterack, Karl A. , Miksch, Timothy, Helmers, Richard A. , Grando, Maria Adela , Grando, Adela , Kaufman, David Ross

Mayo Clinic

Health Informatics Journal | April 15, 2021 | Volume: 27 | Issue: 2 | Pages: No page available

10.1177/14604582211008210 | PMID 33853396 Get It

Rapid ethnography and data mining approaches have been used individually to study clinical workflows, but have seldom been used together to overcome the limitations inherent in either type of method. For rapid ethnography, how reliable are the findings drawn from small samples? For data mining, how accurate are the discoveries drawn from automatic analysis of big data, when compared with observable data? This paper explores the combined use of rapid ethnography and process mining, aka ethno-mining, to study and compare metrics of a typical clinical documentation task, vital signs charting. The task was performed with different electronic health records (EHRs) used in three different hospital sites. The individual methods revealed substantial discrepancies in task duration between sites. Specifically, means of 159.6(78.55), 38.2(34.9), and 431.3(283.04) seconds were captured with rapid ethnography. When process mining was used, means of 518.6(3,808), 345.5(660.6), and 119.74(210.3) seconds were found. When ethno-mining was applied instead, outliers could be identified, explained and removed. Without outliers, mean task duration was similar between sites (78.1(66.7), 72.5(78.5), and 71.7(75) seconds). Results from this work suggest that integrating rapid ethnography and data mining into a single process may provide more meaningful results than a siloed approach when studying of workflow.
Diabetic Kidney Disease Alters the Transcriptome and Function of Human Adipose-Derived Mesenchymal Stromal Cells but Maintains Immunomodulatory and Paracrine Activities Important for Renal Repair
Hickson, LaTonya J. , Eirin, Alfonso , Conley, Sabena M., Taner, Timucin, Bian, Xiaohui , Saad, Ahmed , Mehta, Ramila A. , McKenzie, Travis J. , Kellogg, Todd A., Kirkland, James L. , Saadiq, Ishran M. , Jordan, Kyra L., Zhu, Xiangyang , Griffin, Matthew D. , Wijnen, André J. van , Textor, Stephen C., Lerman, Lilach O. , van Wijnen, Andre J , Griffin, Matthew D , Hickson, LaTonya J , Eirin, Alfonso , Herrmann, Sandra M. , Tchkonia, Tamar , Tang, Hui Jun , Rule, Andrew D.

Mayo Clinic

Diabetes | April 15, 2021 | Volume: 70 | Issue: 7 | Pages: 1561-1574

10.2337/db19-1268 | PMID 33858824 Get It

Mesenchymal stem/stromal cells (MSCs) facilitate repair in experimental diabetic kidney disease (DKD). However, the hyperglycemic and uremic milieu may diminish regenerative capacity of patient-derived therapy. We hypothesized that DKD reduces human MSC paracrine function. Adipose-derived MSC from 38 participants with DKD and 16 control subjects were assessed for cell surface markers, trilineage differentiation, RNA sequencing (RNA-seq), in vitro function (coculture or conditioned medium experiments with T cells and human kidney cells [HK-2]), secretome profile, and cellular senescence abundance. The direction of association between MSC function and patient characteristics were also tested. RNA-seq analysis identified 353 differentially expressed genes and downregulation of several immunomodulatory genes/pathways in DKD-MSC versus Control-MSC. DKD-MSC phenotype, differentiation, and tube formation capacity were preserved, but migration was reduced. DKD-MSC with and without interferon-γ priming inhibited T-cell proliferation greater than Control-MSC. DKD-MSC medium contained higher levels of anti-inflammatory cytokines (indoleamine 2,3-deoxygenase 1 and prostaglandin-E2) and prorepair factors (hepatocyte growth factor and stromal cell–derived factor 1) but lower IL-6 versus control-MSC medium. DKD-MSC medium protected high glucose plus transforming growth factor-β–exposed HK-2 cells by reducing apoptotic, fibrotic, and inflammatory marker expression. Few DKD-MSC functions were affected by patient characteristics, including age, sex, BMI, hemoglobin A1c, kidney function, and urine albumin excretion. However, senescence-associated β-galactosidase activity was lower in DKD-MSC from participants on metformin therapy. Therefore, while DKD altered the transcriptome and migratory function of culture-expanded MSCs, DKD-MSC functionality, trophic factor secretion, and immunomodulatory activities contributing to repair remained intact. These observations support testing of patient-derived MSC therapy and may inform preconditioning regimens in DKD clinical trials.